VKTX250103P38500
- 0.34
- 0.000.00%
Viking Therapeutics Newsroom
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know
Express News | Form 144 | Viking Therapeutics(VKTX.US) Officer Proposes to Sell 8.31 Million in Common Stocks
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Why Viking Therapeutics Stock Plummeted by 24% in December
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
Will Viking Therapeutics, Inc. (VKTX) Make You Rich In 2025?
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Stocks on Sale: Novo Nordisk, Viking Therapeutics, Nike, and Bitcoin
Insider Sellers Might Regret Selling Viking Therapeutics Shares at a Lower Price Than Current Market Value
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark
Why Viking Therapeutics Tumbled by More Than 10% This Week
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla -- WSJ
B.Riley Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $109
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125